Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
BOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS,” authored by Berthiaume, A., and Reda, S., et al., was published in the peer-reviewed journal, Frontiers in Neuroscience. ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
Related news for (ATHA)
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/03/25 05:00 AM
- Today’s Top Performers: MoBot’s Market Review 06/03/25 04:00 AM
- Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
- Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
- Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates